Semin Thorac Cardiovasc Surg. 2011 Winter;23(4):261-2. doi: 10.1053/j.semtcvs.2012.01.003.
The cancer risk in patients with Barrett's esophagus is important because it determines screening, surveillance, and treatment considerations. Previously, the risk of progression to esophageal adenocarcinoma in patients with Barrett's esophagus was thought to be approximately 1%. Recently, 2 very large population-based studies have significantly reduced this risk estimate of cancer. Paradoxically, esophageal adenocarcinoma continues to rise exponentially in the United States. Screening and surveillance programs based on endoscopic, histopathological, and molecular criteria need to be improved to identify a high-risk population of progressors.
巴雷特食管患者的癌症风险很重要，因为它决定了筛查、监测和治疗的考虑因素。以前，人们认为巴雷特食管患者进展为食管腺癌的风险约为 1%。最近，两项非常大的基于人群的研究显著降低了这一癌症风险估计。矛盾的是，在美国，食管腺癌的发病率仍在呈指数级上升。需要改进基于内镜、组织病理学和分子标准的筛查和监测计划，以确定高危进展人群。
